CredoScientia - Bibliothèque

Stage III-IV thymic squamous cell carcinoma in complete pathological remission achieved with thymic cancer resection after immunotherapy combined with chemotherapeutic conversion therapy: a report of two cases from real-world data.

BACKGROUND: Thymic carcinoma, a rare malignancy in the mediastinum, currently lacks standardized treatment options. Although surgery remains a crucial component among traditional therapeutic approache…

Thérapies de Conversion

Li, D., Minervini, F., Planas, G., Okuda, K., Ozeki, N., & Zou, Y. (2024). Stage III-IV thymic squamous cell carcinoma in complete pathological remission achieved with thymic cancer resection after immunotherapy combined with chemotherapeutic conversion therapy: a report of two cases from real-world data.. Gland Surg, 13(1), 117-127. https://doi.org/10.21037/gs-23-488

29/01/2024 Lire →

Conversion practices in Aotearoa New Zealand: Developing a holistic response to spiritual abuse.

Research arising from conversion practices, also known as conversion therapy and sexual orientation and gender identity change efforts, has generally been underpinned by an emancipatory discourse that…

Trauma Psychologique Religieux Abus Spirituels et Emprise Religieuse Thérapies de Conversion

Roguski, M., & Atwool, N. (2024). Conversion practices in Aotearoa New Zealand: Developing a holistic response to spiritual abuse.. PLoS One, 19(5), e0302163. https://doi.org/10.1371/journal.pone.0302163

01/01/2024 Lire →

Conversion therapy for unresectable intrahepatic cholangiocarcinoma using gemcitabine plus S-1 combined with PD-1 inhibitors: a case report.

Intrahepatic cholangiocarcinoma (iCCA) is a highly malignant tumor of the liver and gallbladder, which is usually diagnosed at an advanced stage and the opportunity for surgery is lost. Therefore, con…

Thérapies de Conversion

Zhao, S., Zhang, X., Luo, J., Yan, H., Zhang, J., Lin, R., & Zhu, K. (2024). Conversion therapy for unresectable intrahepatic cholangiocarcinoma using gemcitabine plus S-1 combined with PD-1 inhibitors: a case report.. Front Oncol, 14, 1476593. https://doi.org/10.3389/fonc.2024.1476593

01/01/2024 Lire →

FOLFOX-HAIC combined with targeted immunotherapy for initially unresectable hepatocellular carcinoma: a real-world study.

BACKGROUND: Hepatic arterial infusion chemotherapy (HAIC) with the FOLFOX regimen has demonstrated efficacy in patients with unresectable hepatocellular carcinoma (HCC). The combined targeted and immu…

Thérapies de Conversion

Lu, Y. C., Yang, Y. C., Ma, D., Wang, J. Q., Hao, F. J., Chen, X. X., & Chen, Y. J. (2024). FOLFOX-HAIC combined with targeted immunotherapy for initially unresectable hepatocellular carcinoma: a real-world study.. Front Immunol, 15, 1471017. https://doi.org/10.3389/fimmu.2024.1471017

01/01/2024 Lire →

A case report of a patient with stage IIIa hepatocellular carcinoma complicated by early gastric cancer.

We report a case of patient with Stage IIIa Hepatocellular Carcinoma Complicated by Early Gastric Cancer. Although Stage IIIa liver cancer can be treated with surgery, the overall prognosis of surgery…

Thérapies de Conversion

Song, X., Cai, R., Wang, L., Ding, F., & Ni, H. (2024). A case report of a patient with stage IIIa hepatocellular carcinoma complicated by early gastric cancer.. Front Oncol, 14, 1440171. https://doi.org/10.3389/fonc.2024.1440171

01/01/2024 Lire →

Sarcomatoid carcinoma transformation in oral undifferentiated carcinoma following sequential immune combined targeted therapy: a case report.

The diagnosis and treatment of head and neck undifferentiated carcinoma (HNUC) present significant challenges. Herein, we present the case of a patient with advanced HNUC who underwent conversion surg…

Thérapies de Conversion

Li, J., Zhan, X., Shang, W., & Song, K. (2024). Sarcomatoid carcinoma transformation in oral undifferentiated carcinoma following sequential immune combined targeted therapy: a case report.. Front Immunol, 15, 1484915. https://doi.org/10.3389/fimmu.2024.1484915

01/01/2024 Lire →

Predicting Pathological Response of Neoadjuvant Conversion Therapy for Hepatocellular Carcinoma Patients Using CT-Based Radiomics Model.

PURPOSE: Predicting the pathological response after neoadjuvant conversion therapy for initially unresectable hepatocellular carcinoma (HCC) is essential for surgical decision-making and survival outc…

Thérapies de Conversion

Wen, H., Liang, R., Liu, X., Yu, Y., Lin, S., Song, Z., Huang, Y., Yu, X., Chen, S., Chen, L., Qian, B., Shen, J., Xiao, H., & Shen, S. (2024). Predicting Pathological Response of Neoadjuvant Conversion Therapy for Hepatocellular Carcinoma Patients Using CT-Based Radiomics Model.. J Hepatocell Carcinoma, 11, 2145-2157. https://doi.org/10.2147/JHC.S487370

01/01/2024 Lire →

Case report: Successful radical surgery following complete pathological remission of advanced HCC with Tislelizumab/Lenvatinib plus TACE.

The combination therapy of Tislelizumab plus Lenvatinib has recently emerged as the new standard of care for unresectable hepatocellular carcinoma (HCC). This treatment has demonstrated a significant …

Thérapies de Conversion

Xie, Y., Lyu, T., Zou, Y., & Wang, J. (2024). Case report: Successful radical surgery following complete pathological remission of advanced HCC with Tislelizumab/Lenvatinib plus TACE.. Front Oncol, 14, 1369567. https://doi.org/10.3389/fonc.2024.1369567

01/01/2024 Lire →

"Ethical Care in Secret": Qualitative Data from an International Survey of Exploratory Therapists Working with Gender-Questioning Clients.

This is a mixed methods international survey of therapists ( = 89) belonging to Therapy First, an organization supporting the use of exploratory therapy, rather than gender affirmative therapy, with g…

Thérapies de Conversion

Jenkins, P., & Panozzo, D. (2024). "Ethical Care in Secret": Qualitative Data from an International Survey of Exploratory Therapists Working with Gender-Questioning Clients.. J Sex Marital Ther, 50(5), 557-582. https://doi.org/10.1080/0092623X.2024.2329761

01/01/2024 Lire →

Hepatic Artery Infusion Chemotherapy for Primary and Secondary Malignancies of the Liver: State of the Art and Current High-Level Evidence.

BACKGROUND: Hepatic artery infusion chemotherapy (HAI) has been proposed as a valuable adjunct for multimodal therapy of primary and secondary liver malignancies. This review provides an overview of t…

Thérapies de Conversion

Kuemmerli, C., Hess, V., Dutkowski, P., Sinz, S., Kessler, U., Hess, G. F., Billeter, A. T., Müller-Stich, B. P., Kollmar, O., & Müller, P. C. (2024). Hepatic Artery Infusion Chemotherapy for Primary and Secondary Malignancies of the Liver: State of the Art and Current High-Level Evidence.. Pharmacology, 109(2), 86-97. https://doi.org/10.1159/000537887

01/01/2024 Lire →

Case report: Efficacy of immunotherapy as conversion therapy in dMMR/MSI-H colorectal cancer: a case series and review of the literature.

Immunotherapy has demonstrated a role in the therapeutic landscape of a small subset of patients with colorectal carcinoma (CRC) that harbor a microsatellite instability (MSI-H) status due to a defici…

Thérapies de Conversion

San-Román-Gil, M., Martínez-Delfrade, I., Albarrán-Fernández, V., Guerrero-Serrano, P., Pozas-Pérez, J., Chamorro-Pérez, J., Rosero-Rodríguez, D., Sotoca-Rubio, P., Barrill-Corpa, A. M., Alia-Navarro, V., González-Merino, C., García-de-Quevedo-Suero, C., López, V., Ruz-Caracuel, I., Perna-Monroy, C., & Ferreiro-Monteagudo, R. (2024). Case report: Efficacy of immunotherapy as conversion therapy in dMMR/MSI-H colorectal cancer: a case series and review of the literature.. Front Immunol, 15, 1352262. https://doi.org/10.3389/fimmu.2024.1352262

01/01/2024 Lire →

Transcatheter arterial chemoembolisation combined with lenvatinib plus camrelizumab as conversion therapy for unresectable hepatocellular carcinoma: a single-arm, multicentre, prospective study.

BACKGROUND: The synergistic effect of locoregional therapy in combination with systemic therapy as a conversion therapy for unresectable hepatocellular carcinoma (uHCC) is unclear. The purpose of this…

Thérapies de Conversion

Wu, X. K., Yang, L. F., Chen, Y. F., Chen, Z. W., Lu, H., Shen, X. Y., Chi, M. H., Wang, L., Zhang, H., Chen, J. F., Huang, J. Y., Zeng, Y. Y., Yan, M. L., & Zhang, Z. B. (2024). Transcatheter arterial chemoembolisation combined with lenvatinib plus camrelizumab as conversion therapy for unresectable hepatocellular carcinoma: a single-arm, multicentre, prospective study.. EClinicalMedicine, 67, 102367. https://doi.org/10.1016/j.eclinm.2023.102367

01/01/2024 Lire →